Novel Agent Tolerable, Active for Advanced Colorectal Cancer ...

Basic InformationMore InformationLatest NewsNovel Agent Tolerable, Active for Advanced Colorectal CancerMelanoma Risk Declines With Self-Exams Plus Doctor VisitMissing Follow-Up Colonoscopies Could Raise Colon Cancer RiskProcess Areas for Improvement ID'd in Early Prostate CancerScientists ID Cancer-Causing Agent in Smokeless TobaccoChemo During Pregnancy Doesn't Seem to Harm NewbornNew Drug Appears to Extend Survival in Advanced Prostate Cancer PatientsBiomarker Found to Predict Therapy Benefit in Renal CancerLong-Term Type 2 Diabetes Ups Pancreatic Cancer MortalityAcquired Ovarian Cancer Drug Resistance Linked to GenomesNewer Bone Drug Better for Advanced Breast Cancer Patients: StudyDrug May Aid People With Advanced Thyroid CancerStudy Questions Guidelines on Radiation for Older Breast Cancer PatientsDaily Aspirin May Cut Cancer Deaths, Another Study FindsAdvice From a Cancer Veteran: Do What's Best for YouScreening Debate Typifies Prostate Cancer UncertaintiesMarqibo Approved for Ph- Acute Lymphoblastic LeukemiaCalcium, Vitamin D Supplements May Pose Risks for Men With Prostate CancerWhen Partner Has Breast Cancer, Men Find Their Own Ways to CopeNonoperative Approach Feasible in Advanced Colon CancerGrapefruit Juice May Give Boost to Cancer Treatment: StudyBlood Pressure Drugs Linked to Lip Cancer in StudyGene Subnetworks Predict Risk of Leukemia ProgressionDepression May Affect Survival in Metastatic Renal CancerZaltrap Approved for Advanced Colorectal CancerCould Compact Fluorescent Bulbs Pose Skin Cancer Risk?Common Skin Cancer a Chronic Condition, Study SaysDrug Combo Ups Survival in Metastatic Breast CancerMen With Prostate Cancer Increasingly Don't Die From ItDepression Could Shorten Cancer Survival, Study SuggestsEvidence Grows That Cancer Has Its Own Stem CellsAbandoning PSA Screening Could Cost Lives: StudyScientists Uncover Gene Variation Linked to MelanomaChildbirth After 30 Lowers Risk of Endometrial Cancer: StudyMost Prostate Cancer Patients Don't Die From the Disease: StudyBreast Cancer Doesn't Affect Sexual Function in WomenSelenium, Vitamins C, E May Lower Pancreatic Cancer RiskUntreated Heartburn May Raise Risk for Esophageal Cancer, Study SaysPeople With Darker Skin Still at Risk for MelanomaYounger Cancer Patients' Psychosocial Needs UnmetIf Colonoscopy Picks Up Cancer Risk, Get Next Screen in 5 Years: Study1 in 20 Cases of Melanoma Linked to Tanning Beds: StudyAntioxidants Might Help Cut Pancreatic Cancer Risk, Study SuggestsBortezomib Ups Response, Survival in Multiple Myeloma'Genetic Score' May Improve Prostate Cancer PredictionYoung Cancer Patients Often Lack Support: StudyHeart Medication Converts Cancer Cells Into VaccineSimilar Genetic Alterations in Most Colon, Rectal CancersFDA Gives Nod to New Breast Cancer DrugSerious Mental Illness Tied to Higher Cancer, Injury Risk: StudiesLinksBook Reviews

Updated: Aug 28th 2012

TUESDAY, Aug. 28 (HealthDay News) -- For patients with previously treated metastatic colorectal cancer who are refractory or intolerant to standard therapies, treatment with a novel oral nucleoside antitumor agent, TAS-102, is tolerable and shows promising efficacy, according to a phase 2 study published online Aug. 28 in The Lancet Oncology.

Takayuki Yoshino, M.D., from the National Cancer Center Hospital East in Chiba, Japan, and colleagues assessed the efficacy and safety of TAS-102 for patients with confirmed colorectal adenocarcinoma who had a treatment history of two or more regimens of standard chemotherapy and were refractory or intolerant to fluoropyrimidine, irinotecan, and oxaliplatin. A total of 112 patients (aged 20 or older) were randomly assigned to receive TAS-102, and 57 patients were assigned to placebo. Patients were followed for a median of 11.3 months.

The researchers found that the median overall survival was significantly longer in the TAS-102 group compared with the placebo group (9.0 versus 6.6 months; hazard ratio, 0.56). In the safety population, 50 percent of TAS-102-treated patients had neutropenia of grade 3 or 4, 28 percent had leukopenia, and 17 percent had anemia. None of the placebo-treated patients had grade 3 or worse neutropenia or leukopenia; 5 percent had grade 3 or worse anemia. Serious adverse events occurred in 19 percent of the TAS-102-treated and 9 percent of placebo-treated patients. There were no treatment-related deaths.

"In conclusion, TAS-102 has promising efficacy with a manageable safety profile in patients with metastatic colorectal cancer who are refractory or intolerant to standard chemotherapy," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Taiho Pharmaceuticals, which funded the study and manufactures TAS-102.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

This article: Copyright ? 2012 HealthDay. All rights reserved.

Source: http://www.veridianbh.com/poc/view_doc.php?type=news&id=148959&cn=26

halftime show super bowl halftime show 2012 ahmad bradshaw tom brady halftime super bowl 2012 super bowl score madonna super bowl performance